The dean of Yale's medical school, the incoming president of a prominent cancer group and the head of a Texas cancer center are among leading medical figures who have not accurately disclosed their relationships with drug companies.
Some patients and family members who came to the Houston hospital for liver and lung transplants have complained about the quality of care provided. A St. Luke's spokeswoman says the transplant programs still meet national benchmarks and argues against focusing on outcomes...
After becoming the nation's busiest lung transplant program six years ago, the hospital scaled back the number and difficulty of transplants it performed. For some patients, that meant having to look elsewhere for treatment.
Defibrillator paddles did not work during a patient's heart transplant in January, and a backup set was not nearby. The transplant ultimately failed, and the patient died two months later. His case was featured in a May article.
The hiring of two outside surgeons comes after Medicare terminated funding to the heart transplant program, citing poor outcomes in recent years. Hospital leaders also hired a new top transplant administrator, saying the new staff members will help move the program...
The hospital's chief medical officer resigned last month after failing to disclose company ties in medical journals. Now researchers, including chief executive Dr. Craig B. Thompson, are updating their own conflict-of-interest disclosures.
Christopher Duntsch's surgical outcomes were so outlandishly poor that Texas prosecuted him for harming patients. Why did it take so long for the systems that are supposed to police problem doctors to stop him from operating?